enVVeno Medical Corporation Warrants
NVNOW
NVNOW was delisted on the 26th of May, 2023.
2 hedge funds and large institutions have $1K invested in enVVeno Medical Corporation Warrants in 2022 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more capital invested
Capital invested by funds: $1K → $1K ($0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$267 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $1K | +$267 | +1,127 | +33% |
|
NVNOW Hedge Fund Activity: Q1 2022 in Review
2 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical Corporation Warrants (NVNOW) for Q1 2022, worth a combined $1K — unchanged from a quarter earlier.
Fund positioning in NVNOW was balanced in Q1 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $267.
- 2 institutional investors held enVVeno Medical Corporation Warrants (NVNOW) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $1K of enVVeno Medical Corporation Warrants stock for Q1 2022, unchanged quarter-over-quarter.
- 0 funds opened new enVVeno Medical Corporation Warrants positions in Q1 2022 and 0 closed out.
- The largest enVVeno Medical Corporation Warrants buyer in Q1 2022 was UBS Group, an estimated $267 added.
Based on aggregated 13F filings for Q1 2022.